Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Leukemia · 2024-07 · 38 (7) · 1494-1500
DOI: 10.1038/s41375-024-02230-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, online erschienen am 27.03.2024. Verfasst von Shai Shimony und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated whether molecular ontogeny subgroups have differential benefit of venetoclax (VEN) added to hypomethylating agents (HMA). In secondary ontogeny ( n = 115), median overall survival (OS)(14.1 vs . 6.9 months, P = 0.0054), composite complete remission (cCR 61% vs . 18%, P < 0.001) and allogeneic hematopoietic stem cell transplant (alloHCT) (24% vs . 6%, P = 0.02) rates were better in patients treated with HMA + VEN vs . HMA. In contrast, in TP53 AML( n = 111) median OS (5.7 vs . 6.1, P = 0.93), cCR (33% vs. 37%, P = 0.82) and alloHCT rates (15% vs . 8%, P = 0.38) did not differ between HMA + VEN vs. HMA. The benefit of VEN addition in the secondary group was preserved after adjustment for significant clinicopathologic variables (HR 0.59 [95% CI 0.38–0.94], P = 0.025). The OS benefit of HMA + VEN in secondary ontogeny was similar in those with vs . without splicing mutations ( P = 0.92). Secondary ontogeny AML highlights a group of patients whose disease is selectively responsive to VEN added to HMA and that the addition of VEN has no clinical benefit in TP53 -mutated AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
- Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. coleman_lindsley@dfci.harvard.edu.
ORCID-Profile: Shai Shimony, Jacqueline S Garcia, Marlise R Luskin, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Förderung
- NCI NIH HHS
Zitieren
APA
Shimony, S., Garcia, J. S., Keating, J., Chen, E. C., Luskin, M. R., Stahl, M., Neuberg, D. S., DeAngelo, D. J., Stone, R. M., & Lindsley, R. C. (2024). Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia, 38(7), 1494-1500. https://doi.org/10.1038/s41375-024-02230-w
Vancouver
Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M, et al. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia. 2024;38(7):1494-1500. doi:10.1038/s41375-024-02230-w
BibTeX
@article{Shimony2024,
author = {Shimony, Shai and Garcia, Jacqueline S and Keating, Julia and Chen, Evan C and Luskin, Marlise R and Stahl, Maximilian and Neuberg, Donna S and DeAngelo, Daniel J and Stone, Richard M and Lindsley, R Coleman},
title = {Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients},
journal = {Leukemia},
year = {2024},
volume = {38},
number = {7},
pages = {1494--1500},
doi = {10.1038/s41375-024-02230-w}
}
EUVIMED